Biopharma | May 06, 2026
Emcure crosses US$1 billion revenue milestone in FY26; PAT rises 33%
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
The platform offers personalised recovery plans, AI-driven movement tracking, and access to certified physiotherapists for more than 250 conditions
Conceptualized as an aggregator platform it integrates existing programme systems through an API-based federated architecture
Designed for high-throughput genomic analysis, the laboratory enables accurate, consistent, and scalable testing, delivering high standards of reporting excellence
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
The ISG assessment highlights Indegene’s deep domain expertise, proprietary technology stack, and expanding use of AI and GenAI to drive more integrated, data-led commercial execution across the life sciences value chain
The Minister emphasised that scientific institutions must actively communicate their achievements and engage with stakeholders
The private funding rose 38% amid growing international collaborations and CDMO demand
Subscribe To Our Newsletter & Stay Updated
